Total ARR of $360.5 Million, an Increase of 2% Versus Prior Year. GAAP Net Income of $1.1 Million Versus Net Loss in Prior Year Period. Operating Cash Flow of $5.1 Million ...
Phase 1 dose-escalation trial advancing as planned with non-small cell lung cancer (NSCLC) as the primary target population ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results